Cancer cells harboring EGFR-activating mutations have been shown to be highly sensitive to the EGFR tyrosine kinase inhibitor (TKI) gefitinib, which was first approved in Japan in 2002 [17, 18]. The gene discussed is EGFR; the disease is cancer.